Hypogonadism is a medical condition characterized by inadequate production of testosterone, the primary male sex hormone, by the testes. While TRT has been shown to effectively alleviate symptoms of low testosterone, there has been ongoing debate regarding its potential impact on cardiovascular health and the incidence of Major Adverse Cardiovascular Events (MACE). This is a traverse study and involves topical testosterone replacement therapy (TRT) in symptomatic hypogonadal men with pre-existing cardiovascular disease (CVD) or increased risk for CVD.
Cardiovascular disease and hypogonadism clinical trials are taking place in Little River, South Carolina, to help find potential treatments for the condition.
